Treatment Options for Advanced RAI-R-DTC After Progression on Lenvatinib

A novel scoring system including radiomics data may help clinicians identify the risk of central lymph node metastasis in patients with a subtype of thyroid cancer.

In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.

Lori J. Wirth, MD, discussed advancements in diagnosing and treating thyroid cancer, offering community oncologists improved tools for identifying low-risk cancers, personalizing treatment, and exploring innovative approaches.

Whole-exome sequencing identified genetic mutations associated with poorly differentiated thyroid cancer, paving a new path for research in the field.

Health-related, mental, and emotional quality of life often suffer when patients with thyroid cancer undergo thyroidectomy. However, research shows it may be only in the short-term.

In an interview with Targeted Oncology, Francis P. Worden, MD, shed light on the evolving landscape of advanced thyroid cancer treatment, offering valuable insights into the available options.